ARCT

Arcturus Therapeutics Holdings Inc. [ARCT] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

ARCT Stock Summary

Top ARCT Correlated Resources

ARCT


Top 10 Correlated ETFs

ARCT


Top 10 Correlated Stocks

ARCT


In the News

08:30 11 Dec 2023 ARCT

Arcturus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that Joseph Payne, President & Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, on Tuesday, January 9, 2024, at 3:00 p.

09:01 11 Dec 2023 ARCT

Arcturus' (ARCT) CF Drug Gets FDA's Orphan Status, Stock Up

Arcturus (ARCT) rises 8% as the FDA grants Orphan Drug Designation for its product candidate, ARCT-032, for the treatment of cystic fibrosis.

03:01 11 Dec 2023 ARCT

From Financial Metrics To mRNA Milestones: Arcturus Therapeutics' Evolving Journey

Arcturus Therapeutics is a biotech firm focused on mRNA vaccine development and delivery technologies. The company's core investment thesis is centered around its cutting-edge research and its ability to derive revenue from its collaborations. The potential approval of its first vaccine will work as a proof-of-concept for its mRNA platform and will likely raise the market expectations.

08:38 11 Dec 2023 ARCT

Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2023 Earnings Call Transcript

Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2023 Earnings Call Transcript

10:56 11 Dec 2023 ARCT

The 3 Most Undervalued Biotech Stocks to Buy: November 2023

These companies in the biotechnology sector are doing incredible work and achieving wonderful developments. The result is not not only growth and profit for the companies, but they are also offering excellent and efficient solutions for the health of each one of us.

04:01 11 Dec 2023 ARCT

Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 14, 2023

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended September 30, 2023 after the market close on Tuesday, November 14 and will also host a conference call and webcast at.

05:35 11 Dec 2023 ARCT

Arcturus: Interim Readout Of Rare Disease Data In Coming Months

Results from phase 2 study using ARCT-810 for the treatment of patients with Ornithine-Transcarbamylase [OTC] deficiency are expected in the coming months. The Ornithine-Transcarbamylase Deficiency market is expected to reach $930.33 million by 2030. A phase 1 study of ARCT-032 for Cystic Fibrosis was completed and clearance was given to begin a phase 1b study.

08:30 11 Dec 2023 ARCT

Arcturus Therapeutics to Attend Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will participate in the following investor conferences: Citi's 18th Annual BioPharma Conference 2023 (Hosting 1x1 meetings) Wednesday, September 6 – 7, 2023 2023 Wells Fargo Heal.

08:30 11 Dec 2023 ARCT

New Strong Sell Stocks for August 10th

ARCT, AVY and ASB have been added to the Zacks Rank #5 (Strong Sell) List on August 10, 2023.

02:39 11 Dec 2023 ARCT

Why Shares of Arcturus Therapeutics Dropped on Tuesday

Arcturus Therapeutics has several collaboration agreements. The company is a clinical-stage biotech.

ARCT Financial details

Company Rating
Strong Buy
Market Cap
635.75M
Income
99.33M
Revenue
292.72M
Book val./share
10.54
Cash/share
11.74
Dividend
-
Dividend %
-
Employees
170
Optionable
No
Shortable
Yes
Earnings
14 Nov 2023
P/E
6.36
Forward P/E
-5.81
PEG
-0.43
P/S
2.17
P/B
2.26
P/C
1.98
P/FCF
4.64
Quick Ratio
3.99
Current Ratio
4.49
Debt / Equity
0.18
LT Debt / Equity
0.17
-
-
EPS (TTM)
3.75
EPS next Y
-4
EPS next Q
-1.19
EPS this Y
-104.45%
EPS next Y
-206.67%
EPS next 5Y
-206.67%
EPS last 5Y
NAN%
Revenue last 5Y
67.19%
Revenue Q/Q
353.49%
EPS Q/Q
-69.19%
-
-
-
-
SMA20
26.32%
SMA50
-7.69%
SMA100
-29.41%
Inst Own
76.77%
Inst Trans
0.87%
ROA
22%
ROE
34%
ROC
0.17%
Gross Margin
101%
Oper. Margin
21%
Profit Margin
34%
Payout
-
Shs Outstand
26.72M
Shs Float
24.33M
-
-
-
-
Target Price
19.5
52W Range
14.21-37.75
52W High
-37.24%
52W Low
+65.86%
RSI
53
Rel Volume
0.4
Avg Volume
404.54K
Volume
163K
Perf Week
-6.63%
Perf Month
24.44%
Perf Quarter
-5.72%
Perf Half Y
-15.53%
-
-
-
-
Beta
2.582
-
-
Volatility
0.37%, 2.51%
Prev Close
-2.4%
Price
23.22
Change
-4.84%

ARCT Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
1.561.720.470.477.78
Net income per share
-2.16-2.13-3.51-7.860.35
Operating cash flow per share
-2.06-0.53-2.11-5.131.21
Free cash flow per share
-2.21-0.6-2.2-5.260.92
Cash per share
3.655.9122.814.0814.82
Book value per share
1.352.1419.538.6710.22
Tangible book value per share
1.352.1419.538.6710.22
Share holders equity per share
1.352.1419.538.6710.22
Interest debt per share
11.751.042.673.45
Market cap
45.61M131.19M880.83M973.99M448.51M
Enterprise value
18.81M79.68M435.81M671.11M147.5M
P/E ratio
-2.09-5.1-12.34-4.7147.97
Price to sales ratio
2.96.3192.3478.812.18
POCF ratio
-2.2-20.36-20.55-7.2114.02
PFCF ratio
-2.05-18.06-19.75-7.0418.48
P/B Ratio
3.345.092.224.271.66
PTB ratio
3.345.092.224.271.66
EV to sales
1.193.8345.6954.30.72
Enterprise value over EBITDA
-0.9-3.12-6.07-3.3512.65
EV to operating cash flow
-0.91-12.36-10.17-4.974.61
EV to free cash flow
-0.85-10.97-9.77-4.856.08
Earnings yield
-0.48-0.2-0.08-0.210.02
Free cash flow yield
-0.49-0.06-0.05-0.140.05
Debt to equity
0.730.80.050.30.34
Debt to assets
0.220.250.040.170.2
Net debt to EBITDA
1.282.026.21.51-25.81
Current ratio
3.333.489.453.813.18
Interest coverage
-117.26-57.2-198.13-75.8628.99
Income quality
0.950.250.590.663.42
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
1.310.612.433.350.22
Research and developement to revenue
1.081.626.0614.060.72
Intangibles to total assets
00000
Capex to operating cash flow
0.070.130.040.03-0.24
Capex to revenue
-0.09-0.04-0.18-0.28-0.04
Capex to depreciation
-2.54-1.2-1.98-2.85-5.06
Stock based compensation to revenue
0.080.10.712.340.15
Graham number
8.1210.1239.339.169.02
ROIC
-0.94-0.49-0.17-0.690.03
Return on tangible assets
-0.49-0.31-0.15-0.530.02
Graham Net
0.941.3818.947.928.09
Working capital
29.25M52.97M418.27M279.42M276.35M
Tangible asset value
13.64M25.79M396.55M228.21M270.31M
Net current asset value
11.27M17.94M387.89M214.36M223.26M
Invested capital
0.730.80.050.30.34
Average receivables
2.48M3.33M2.15M2.75M3.07M
Average payables
2.09M4.1M8.28M10.42M8.75M
Average inventory
730K0000
Days sales outstanding
103.8338.2681.3199.444.9
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
3.529.544.493.6774.44
Payables turnover
00000
Inventory turnover
00000
ROE
-1.6-1-0.18-0.910.03
Capex per share
-0.15-0.07-0.09-0.13-0.29

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.516.0430.361.63
Net income per share
-1.34.431.91-1.98-0.61
Operating cash flow per share
-1.66.05-1.351.91-1.22
Free cash flow per share
-1.685.9-1.381.9-1.26
Cash per share
8.9814.7812.3512.1811.74
Book value per share
5.510.212.410.7410.54
Tangible book value per share
5.510.212.410.7410.54
Share holders equity per share
5.510.212.410.7410.54
Interest debt per share
3.613.461.281.211.93
Market cap
392.24M449.58M636.52M761.83M678.97M
Enterprise value
249.31M148.56M337.78M470.56M414.07M
P/E ratio
-2.840.963.14-3.62-10.46
Price to sales ratio
29.342.817.9879.6515.65
POCF ratio
-9.252.81-17.7414.99-20.95
PFCF ratio
-8.82.87-17.4115.1-20.34
P/B Ratio
2.691.661.932.672.42
PTB ratio
2.691.661.932.672.42
EV to sales
18.650.934.2449.29.55
Enterprise value over EBITDA
-6.941.19-17.9-9.16-21.43
EV to operating cash flow
-5.880.93-9.429.26-12.78
EV to free cash flow
-5.590.95-9.249.33-12.4
Earnings yield
-0.090.260.08-0.07-0.02
Free cash flow yield
-0.110.35-0.060.07-0.05
Debt to equity
0.650.340.10.110.18
Debt to assets
0.320.20.070.070.11
Net debt to EBITDA
3.98-2.415.835.6713.71
Current ratio
3.253.184.714.264.49
Interest coverage
-48.11153.7419.860-965.7
Income quality
1.21.37-0.71-0.972
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.930.070.171.380.31
Research and developement to revenue
2.820.170.655.511.18
Intangibles to total assets
00000
Capex to operating cash flow
0.05-0.020.02-0.010.03
Capex to revenue
-0.16-0.02-0.01-0.04-0.02
Capex to depreciation
-5.24-6.91-1.2-0.48-1.19
Stock based compensation to revenue
0.710.040.10.880.21
Graham number
12.7131.8723.0921.8612.03
ROIC
-0.130.310.04-0.16-0.06
Return on tangible assets
-0.120.260.11-0.12-0.04
Graham Net
3.458.079.637.826.79
Working capital
170.83M276.35M334.43M294.9M305.59M
Tangible asset value
145.67M270.31M329.25M285.18M280.06M
Net current asset value
98.72M223.26M282.94M239.77M215.68M
Invested capital
0.650.340.10.110.18
Average receivables
2.15M2.4M47.62M47.64M20.51M
Average payables
11.86M12.71M13.4M16.48M15.99M
Average inventory
00027.5M45M
Days sales outstanding
13.761.55104.426.3479.3
Days payables outstanding
00-3.13K-1.28K0
Days of inventory on hand
000-5.19K0
Receivables turnover
6.5457.90.863.421.13
Payables turnover
00-0.03-0.070
Inventory turnover
000-0.020
ROE
-0.240.430.15-0.18-0.06
Capex per share
-0.08-0.14-0.03-0.01-0.04

ARCT Frequently Asked Questions

What is Arcturus Therapeutics Holdings Inc. stock symbol ?

Arcturus Therapeutics Holdings Inc. is a US stock , located in San diego of Ca and trading under the symbol ARCT

Is Arcturus Therapeutics Holdings Inc. buy or a sell ?

3 stock analysts have 3 predictions with a medium analyst target price of $23. The lowest prediction is $14 and the highest is $30

What is ARCT stock prediction ?

What is Arcturus Therapeutics Holdings Inc. stock quote today ?

Arcturus Therapeutics Holdings Inc. stock price is $23.22 today.

Is Arcturus Therapeutics Holdings Inc. stock public?

Yes, Arcturus Therapeutics Holdings Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap